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Abstract
Background: Metallothionein 3 (MT3) maintains intracellular metal homeostasis and protects against reactive oxygen
species (ROS)-induced DNA damage. In this study, we investigated the epigenetic alterations and gene expression of the
MT3 gene in esophageal adenocarcinomas (EACs).
Methods and Results: Using quantitative bisulfite pyrosequencing, we detected unique DNA methylation profiles in the
MT3 promoter region. The CpG nucleotides from 2372 to 2306 from the transcription start site (TSS) were highly
methylated in tumor (n=64) and normal samples (n=51), whereas CpG nucleotides closest to the TSS (24 and +3)
remained unmethylated in all normal and most tumor samples. Conversely, CpG nucleotides in two regions (from 2139 to
249 and +296 to +344) were significantly hypermethylated in EACs as compared to normal samples [FDR,0.001,
2log10(FDR).3.0]. The DNA methylation levels from 2127 to 28 CpG sites showed the strongest correlation with MT3
gene expression (r=20.4, P,0.0001). Moreover, the DNA hypermethylation from 2127 to 28 CpG sites significantly
correlated with advanced tumor stages and lymph node metastasis (P=0.005 and P=0.0313, respectively). The ChIP
analysis demonstrated a more repressive histone modification (H3K9me2) and less active histone modifications (H3K4me2,
H3K9ace) in OE33 cells than in FLO-1 cells; concordant with the presence of higher DNA methylation levels and silencing of
MT3 expression in OE33 as compared to FLO-1 cells. Treatment of OE33 cells with 5-Aza-deoxycitidine restored MT3
expression with demethylation of its promoter region and reversal of the histone modifications towards active histone
marks.
Conclusion: In summary, EACs are characterized by frequent epigenetic silencing of MT3. The choice of specific regions in
the CpG island is a critical step in determining the functional role and prognostic value of DNA methylation in cancer cells.
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Introduction
Esophageal adenocarcinoma (EAC) is one of the human
malignancies with the fastest growing incidence rates in the
Western world [1,2,3]. It is generally considered that EAC
develops from a premalignant lesion of Barrett’s esophagus (BE)
[3,4]. BE is an acquired condition in which the normal squamous
cell epithelium of the esophagus is replaced by a metaplastic
columnar epithelium [5,6]. Chronic gastro-esophageal reflux
disease (GERD), with accumulation of reactive oxygen species
(ROS) and subsequent oxidative DNA damage, is one of the main
risk factors for the development of BE and its progression to
adenocarcinoma [7,8,9,10]. Hypermethylation of the gene
promoter CpG islands is one of the major mechanisms to silence
tumor suppressor genes and other tumor related genes [11,12]. In
addition to DNA methylation, other epigenetic alterations such as
histone modifications, histone acetylation, and methylation are
also involved in the regulation of gene expression [13,14,15].
Epigenetic cross talk between DNA methylation and histone
modifications occurs through various physiologic and pathologic
conditions. The combination of these dynamic interactions
determines gene expression [16,17].
Metallothioneins (MTs) are low in molecular weight (7 kDa)
and are cysteine-rich proteins that are involved in maintaining
intracellular metal homeostasis by binding transition metals such
as zinc and copper [18,19]. In mammalians, four members of the
MT family have been identified [20]. The MTs play an important
role in protecting against DNA damage, apoptosis and oxidative
stress [20]. MT3 was discovered as an inhibitory neuronal growth
factor that is involved in the reparative and/or protective processes
in the brain and becomes down-regulated in Alzheimer’s disease
[21,22]. The role of MT3 in tumorigenesis is unclear and the
reported results were inconsistent. The levels of the MT3 protein
are elevated in bladder [23], breast [24] and prostate cancers [25];
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Conversely, DNA methylation of the MT3 promoter has been
associated with the down-regulation of the MT3 gene in gastric
carcinoma [26] and esophageal squamous cell carcinoma [27].
Recent studies suggest that MT3 is involved in the protection of
reactive oxygen species-induced DNA damage [28]. MT3
prevents the gamma-radiation-induced 8-oxoG accumulation
and mutation in normal and hOGG1-depleted cells [29]. Because
of MT3s antioxidant functions, we investigated the expression of
MT3 and its epigenetic regulation in esophageal adenocarcinoma.
Our results demonstrated epigenetic silencing of MT3 through
promoter DNA hypermethylation and repressive histone modifi-
cation mechanisms.
Results
Changes of DNA methylation levels in MT3 promoter
region
Our analysis indicated that the human MT3 gene contains a
large CpG island located from 2372 bp upstream of the
transcript start site (TSS) to approximately +344 bp downstream
of the TSS (Figure 1A). To determine the DNA methylation
change of the CpG island, we designed several Pyrosequencing
assays that enabled us to perform quantitative analysis of the
DNA methylation level of each of the 59 CpG nucleotides using a
state-of-the-art Pyrosequencing technique (Figure 1A). A heat
map of the DNA methylation levels of each of the CpG sites from
2372 to +344 of the TSS in NS (normal esophageal squamous
epithelia), NG (normal gastric epithelia), BE, and EAC is shown
in Figure 1B. A distant upstream region of CpG nucleotides from
2372 to 2306 displayed non-exclusive high level DNA
methylation in all the normal and tumor samples (The 6 CpG
sites at the left side in Figure 1B). This finding suggests that this
region may not play a critical role in transcription regulation of
MT3 during EAC carcinogenesis, and was excluded from further
analysis. On the other hand, the normal samples (both NS and
NG) displayed universal low levels of DNA methylation in the
remaining CpG sites (Figure 1B), suggesting that the ‘‘field
defect’’ phenomenon may not play a significant role in the
regulation of MT3 gene expression. There was a significant
difference in the DNA methylation level between EACs and both
normal esophagus (NS) and normal stomach (NG) samples in
almost all CpG nucleotides in the region from 2161 to +344
(FDR,0.01, 2log10(FDR).2, Figure 1C). However, CpG
nucleotides in two regions (2139 to 249 and +296 to +344)
were more significant than all other sites (FDR,0.001,
2log10(FDR).3.0, Figure 1C). Interestingly, DNA methylation
changes in this region displayed a biphasic methylation pattern in
primary EACs: declining to ,10% towards the TSS as seen in
CpG nucleotides at 24a n d+3 of TSS (Figure 2A). In our
Figure 1. DNA methylation levels of the MT3 promoter in esophageal adenocarcinomas and normal tissue samples. A) Schematic
illustration of MT3 genomic structure and the Pyrosequencing and ChIP assays. The MT3 gene comprises of 3 exons (black boxes). There is a long CpG
island extending from upstream of the transcription start site (TSS) to the first intron (grey box). Each grey vertical bar represents one individual CpG
site from 2372 to +344. Four Pyrosequencing assays (assay 1–4) and three ChIP assays (ChIP 1–3) are shown. B) Heat map of DNA methylation profile
from 2372 to +344 in normal esophageal squamous mucosa (NS), normal gastric glandular mucosa (NG), Barrett’s esophagus (BE) and esophageal
adenocarcinoma (EAC) samples. A key for the blue scale is given below the map. Grey areas indicate missing data. C) Significance analysis of DNA
methylation levels in the MT3 promoter region from 2161 to +344 of TSS between EAC and normal samples. Each dot or cycle represents one
comparison between tumor and normal samples for one CpG site, as indicated. The graph is plotted for the mean value in all tumor samples, as
compared to the mean value for all normal samples (NS or NG) in each CpG site. FDR (false discovery rate) was used to demonstrate the significance
and is plotted as 2log10(FDR) in y axis. Thus, if FDR,0.01 then 2log10(FDR).2.0. We used FDR#0.01 as the cutoff for statistical significance.
doi:10.1371/journal.pone.0022009.g001
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subregions. The CpG nucleotides from 2161 to 2130 of the TSS
(Region 1, R1) displayed increased DNA methylation in normal
samples (10–25%). The methylation levels of these sites in normal
stomach samples (NG) were significantly higher than in normal
esophagus (NS, P,0.01). BE and EAC samples had higher DNA
methylation levels than in normal samples (P,0.01 among N,
BE, EAC, and between them, Figure 2B). The CpG nucleotides
from 2127 to 28 (Region 2, R2) demonstrated low methylation
levels (below 10%) in both normal esophagus and stomach with a
significant increase in the methylation levels in BE and EACs
(P,0.001 among N, BE, EAC, Figure 2B). Similarly, the CpG
nucleotides from +28 and +344 (Region 3, R3) showed low
methylation levels in normal esophagus and stomach samples.
However, this region showed similar higher methylation levels in
BE and EACs, in particular, in sites from +28 to +277 (Figure 2A).
DNA hypermethylation of the specific CpG nucleotides in
EACs and correlation with down-regulation of MT3 gene
expression
According to the unique DNA methylation changes shown
above, the region from 2161 to +344 in the MT3 promoter was
considered to be important in esophageal adenocarcinogenesis. To
explore the relative importance of the different subregions of this
long promoter in regulating MT3 gene expression, 115 RNA
samples from the same frozen tissues that were used for DNA
methylation analysis were subjected to real-time RT-PCR analysis
Figure 2. Biphasic changes of DNA methylation levels in MT3 promoter region from 2160 to +344. A) The analysis included esophageal
adenocarcinoma (EAC, n=78), Barrett’s esophagus (BE, n=5), normal glandular gastric mucosa (NG, n=28), and normal squamous esophageal
mucosa (NS, n=30). A biphasic DNA methylation change pattern was demonstrated in BE and EAC. According to the different DNA methylation
patterns, we divided this region into 3 subregions (R1, R2 and R3) for further analysis. B) Statistical analysis of the DNA methylation level in R1, R2 and
R3 in NS, NG, N, BE, and EAC. Each dot represents the average DNA methylation level of corresponding group samples of one CpG site. N is the mean
of NS and NG. The horizontal bars in each group represent the mean methylation level. The difference of the DNA methylation levels between NS and
NG were calculated with the Mann-Whitney test. The difference among N, BE and EAC and between pairs was calculated with ANOVA of Newman-
Keuls test. ** indicates P,0.01, ns=not significant.
doi:10.1371/journal.pone.0022009.g002
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with the high level DNA methylation in primary EACs, we
detected significantly down-regulated MT3 gene expression in
EACs compared to normal esophagus and stomach samples
(Figure 3A and 3B). We further compared the relative MT3
expression fold to the average DNA methylation level of the CpG
nucleotides in Regions 1, 2, and 3 using a Spearman correlation
analysis. As shown in Figure 3C, significant reverse correlation
between MT3 DNA methylation and the MT3 mRNA expression
were observed in R2 (from 2127 to 28, r=20.4, p,0.0001) and
R3 (from +28 to +344, r=20.3, p=0.005). The strongest
correlation was found to be in Region 2 where 63% (49/78) of
EACs were hypermethylated ($10% methylation level). Taken
together, our results indicate that Region 2 (from 2127 to 28) is
the most suitable region for functional analysis of the MT3
promoter methylation; since it was frequently hypermethylated in
EACs, had the strongest inverse correlation between DNA
methylation and gene expression (Figure 3C), and was the best
discriminating region between tumor and normal samples
(Figure 1B).
5-Aza administration restores the expression of MT3
To validate if DNA methylation is responsible for the gene
silencing, an esophageal adenocarcinoma cell line (OE33) was
treated with 5-Aza and TSA, as described in the Methods section.
As shown in Figure 4, both 5-Aza alone and 5-Aza followed by
TSA treatment restored MT3 gene expression in a previously
silenced OE33 cell line accompanied by significant demethylation
of a previously methylated promoter. TSA treatment alone did not
have an effect on MT3 promoter methylation.
DNA methylation of the MT3 gene promoter region
associated with repressor histone modifications
FLO-1 and OE33 cell lines were selected for the ChIP assays,
based on their variable methylation and expression levels of MT3.
OE33 cells have a high level of DNA methylation (74% for Region
2) and almost silenced MT3 expression, whereas FLO-1 cells
express MT3 and have a low level of DNA methylation (9% for
Region 2) (Figure 5A). To examine if the DNA hypermethylation
of the MT3 gene promoter region is associated with additional
repressor histone modifications, the chromatin immunoprecipita-
tion assay (ChIP) was carried out using specific antibodies against
H3, H3K4 dimethylation (H3K4me2), H3K9 dimethylation
(H3K9me2), and H3K9 acetylation (H3K9ace). Three indepen-
dent assays were developed along different regions of the MT3
promoter as shown in Figure 1A and Table 1. FLO-1 cells showed
a very low level of repressive histone H3K9me2 as compared to
histone H3K4me2 and H3K9ace (Figure 5B). In contrast, the
Figure 3. DNA methylation of the MT3 promoter correlates with MT3 gene expression. A) Comparison of MT3 gene expression between
esophageal adenocarcinoma (EAC) and normal samples (N includes normal squamous esophageal mucosa (NS) and normal glandular gastric mucosa
(NG)). B) MT3 gene expression in 32 matched normal (N) and tumor (EAC) pairs. C) The differential correlation power of Region 1 (R1, from 2161 to
2130), Region 2 (R2, from 2127 to 28) and Region 3 (R3, from +28 to +344) was demonstrated. Spearman correlation analysis was used to evaluate
the significance between MT3 DNA methylation and mRNA expression. The Mann-Whitney test was used in A and B analyses.
doi:10.1371/journal.pone.0022009.g003
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to the other two histones (Figure 5C). Administration of 5-Aza
(5 uM) to OE33 cells for 72 h reversed the relative abundance of
the histone modifications towards active expression. There was a
decrease in the level of H3K9me2 to MT3 promoter regions and
an increase in H3K4ac and H3K4me2 (Figure 5D).
DNA methylation of the MT3 gene promoter region
associated with advanced tumor stages
To investigate if MT3 promoter methylation is associated with
tumor biology, we performed statistical analysis between DNA
methylation and clinicopathological parameters. As shown in
Figure 6, DNA methylation of R2 (from 2127 to 28 CpG sites)
was significantly associated with advanced tumor stages (P=0.005)
and lymph node metastasis (P=0.031). However, DNA methyl-
ation R3 (from +28 to +344 sites) was only associated with tumor
stage (P=0.033) but not with lymph node metastasis (P=0.45).
Discussion
In this study, we demonstrated a unique DNA methylation
pattern along the promoter CpG island of the MT3 gene. The
MT3 CpG island demonstrated variable degrees of methylation.
Interestingly, several CpG nucleotides were highly methylated in
tumor and normal samples (from 2372 to 2306) whereas CpG
nucleotides closest to the TSS (from 24 and +3) remained
unmethylated in all normal and most tumor samples. On the other
hand, CpG nucleotides in two regions (from 2139 to 249 and
+296 to +344) were more significantly hypermethylated in EACs
as compared to normal samples (FDR,0.001,
2log10(FDR).3.0). The methylation pattern in BE was similar
to that in EACs; however, BE had an extended region with
unmethylated CpG nucleotides around the TSS (from 269 to +3).
These results suggest the existence of some protective mecha-
nism(s) that prevent the core region of the TSS from methylation
in normal conditions [30,31]. Although the mechanisms explain-
ing progressive methylation patterns remain unclear, recent studies
suggested that dimethylation of lysine 4 of histone 3 (H3K4me2)
may protect against DNA methylation [32,33]. Our ChIP results
also support this hypothesis by showing a high level of H3K4me2
in an active MT3 promoter (in particular, in ChIP 2) in the FLO-1
cell line and a significantly decreased level of H3K4me2 in a
suppressive promoter in OE33.
The unexpected variable methylation levels in the MT3
promoter CpG island highlight the critical importance of selecting
the proper promoter sites for DNA methylation studies in cancer.
Comprehensive analysis of the promoter regions using quantitative
techniques such as Pyrosequencing may be important for
identifying crucial promoter region(s) that regulate gene expres-
sion. This is best exemplified by our results in the region from
2372 to 2306, where DNA methylation was high in all samples
including normal tissues without any correlation with the gene
expression levels. On the other hand, the strongest inverse
correlation between DNA methylation and gene expression was
present in R2 (from 2127 to 28), suggesting that this region may
be critical in regulating MT3 gene expression. Significance
analysis demonstrated that R2 has the smallest false discovery
rate (FDR,0.001, 2log10(FDR).3) in differentiating EACs from
both NS and NG. The difference between BE and normal tumors
(NS+NG) and between EACs and BE were also statistically
significant (p,0.01, respectively). Taken together, our findings
suggest that R2 is the most suitable region to examine DNA
methylation that possibly plays a critical role in transcription
regulation of MT3. We, and others, have shown that DNA
methylation could be an early event in carcinogenesis [34,35,36].
Our analysis of a few BE samples that were available for DNA
methylation analysis suggested that R1 and R3 of the MT3
promoter may be early events occurring in BE. However, a study
using a large panel of precancerous lesions, including Barrett’s
dysplasia samples, is needed to fully understand the progressive
mode of MT3 methylation in the early stages of Barrett’s
carcinogenesis.
Using an in vitro cell model of EAC, we confirmed that DNA
methylation is the mechanism underlying MT3 gene silencing. In
Figure 4. Treatment with 5-Aza and TSA reverses DNA methylation and gene expression patterns of MT3. An esophageal
adenocarcinoma cell line (OE33) in which the MT3 gene is silenced and the MT3 promoter CpG island was highly methylated, were treated with 5-Aza
and TSA as described in the Methods section. DNA methylation level was determined by Pyrosequencing in Region 2 (from 2127 to 28). MT3 gene
mRNA expression level was determined by real-time RT-PCR and normalized to HPRT to generate a relative fold induction. The 5-Aza treatment alone
led to the induction of relative expression from 0.01 fold to 1.1 whereas the combination of 5-Aza and TSA led to an increase to 17.8.
doi:10.1371/journal.pone.0022009.g004
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promoter region and restored MT3 gene expression, concordant
with many other reports [35,37]. Histone modifications including
histone acetylation and methylation are important regulators of
gene expression. Generally, active chromatin is associated with
histone acetylation of H3K9 and methylation of H3K4, H3K36
and H3K79 while repressive chromatin is associated with histone
deacetylating of H3K9 and methylation of H3K9, H3K27 and
H4K20 [14,38]. The final outcome of gene expression may be
determined by the overall changes of these modifications, in
addition to DNA methylation. We carried out ChIP assay followed
by qPCR using two esophageal adenocarcinoma cell lines; FLO-1,
which expresses MT3 and has a low level of DNA methylation;
and OE33, which has hypermethylated promoter and silenced
MT3. Analysis of three different regions of the MT3 promoter
demonstrated significantly high levels of H3K4me2 and H3K9ace,
and low levels of H3K9me2 in all three regions in FLO-1 cells.
OE33 showed the converse results with an increased ratio of
repressive to active histone H3K9 (H3K9me2/H3K9ace). The 5-
Aza administration in the methylated OE33 cells reversed the ratio
of repressive to active histone H3K9, showing higher levels of
H3K9ace than H3K9me2. These results indicate that DNA
methylation of the MT3 gene is linked with unique histone
modifications in regulating gene expression. Surprisingly, the
H3K4me2 level did not disappear completely, even in the highly
methylated OE33 promoter. After 5-Aza treatment of OE33 cells,
H3K4me2 showed a significant increase only in the ChIP3 region
not in the ChIP2 region where the strongest correlation between
Figure 5. Quantitative Chromatin Immunoprecipitation (ChIP) assay of the MT3 promoter. The three ChIP assays of the MT3 promoter are
shown in Figure 1A and Table 1. All ChIP experiments were performed in triplicates for each assay. Following quantitative real-time PCR (qPCR), the
percent of relative of DNA binding in B, C and D was determined by normalizing the indicated histone binding level to its corresponding input and
H3 levels. A relative percent of occupancy of three histones is shown. A) DNA methylation levels in the CpG nucleotides from 2161 to +344 in OE33
and FLO-1 cell lines demonstrate a lower methylation level in FLO-1 cells. B) ChIP-qPCR in FLO-1 cells, demonstrate relatively low levels of repressive
histone H3K9me2 as compared to histone H3K4me2 and H3K9ace. C) ChIP-qPCR results in the OE33 cell line show high levels of H3K9me2 as
compared to the other two histones. D) ChIP-qPCR results in OE33 cell line, following administration of 5 mM 5-Aza for 72 h, reversed the relative
abundance of the histone modifications towards active expression.
doi:10.1371/journal.pone.0022009.g005
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results suggest that H3K4me2 may not be directly associated with
MT3 gene expression. While some reports indicated that
H3K4me2 is associated with active chromatin [39,40] others
demonstrated that H3K4me2 could be present on poised and
inactive genes [14,41]. The histone modifications and their
relationship with DNA methylation and gene expression are quite
complex [16,38]. Further studies are needed to understand the
complexity of epigenetic mechanisms in transcription regulation.
Interestingly, we found that DNA methylation of the MT3
promoter region (R2, from 2127 to 28 sites) was significantly
associated with advanced tumor stages and lymph node metastasis
(Figure 6), indicating that dysfunction of MT3 through DNA
methylation of the core promoter region may be associated with
tumor progression. These results further confirm the importance
of selecting the appropriate promoter regions for the study of DNA
methylation in cancer.
In conclusion, we demonstrated frequent silencing of MT3
expression in esophageal adenocarcinomas due to unique DNA
methylation changes and histone modifications. The biological
functions of MT3 in regulating ROS and oxidative stress in other
diseases call for investigations along this line in esophageal
carcinogenesis. The choice of a promoter region to examine
DNA methylation is a critical step that should be carefully
considered in molecular studies of carcinogenesis and in the
development of early detection biomarkers.
Materials and Methods
Ethics Statement
De-identified human tissue samples were obtained from the
archives of pathology at Vanderbilt University (Nashville, TN,
USA), Erlangen University (Erlangen, Germany) and from the
National Cancer Institute Cooperative Human Tissue Network
(CHTN). The use of specimens was approved by the Institutional
Review Board at Vanderbilt University Medical Center. All
patients provided written consent, and samples were collected after
surgical resection. All tissue samples that were included in this
study were collected from tissues that remained after the
completion of diagnosis, and are otherwise discarded.
Cell lines
Esophageal adenocarcinoma cell lines, OE33 and FLO-1 [42],
were cultured in Dulbecco’s modified Eagle’s medium (DMEM)
media supplemented with 10% fetal bovine serum (FBS) and
antibiotics (Invitrogen, Carlsbad, CA, USA) in a 37uC incubator
with 5% CO2.
Tissue samples
For DNA and mRNA analysis, 144 frozen tissue samples (78
EACs, 5 BE, 33 normal esophagus, and 28 normal stomach
samples) were collected. The normal esophagus and stomach
samples were taken from tumor-free margins of resected tumors
and were histologically normal. Histopathological diagnosis of the
BE and EAC was verified on the basis of H&E-stained sections,
according to the Vienna classification of gastrointestinal epithelial
neoplasia [43]. Fresh tissue samples were quickly rinsed in liquid
nitrogen then embedded in optimal cutting temperature (OCT). A
section was cut and H&E-stained. Tissue dissection was performed
from OCT blocks, based on H&E staining, to obtain $70% tumor
cell purity. All adenocarcinomas were classified according to the
recent guidelines of the International Union Against Cancer
(UICC) TNM classification system. All EACs originated from the
lower esophagus or gastro-esophageal junction corresponding to
the adenocarcinoma of the esophago-gastric junction [44]. The
patients’ ages ranged from 34–82 years (median at 63 years). The
adenocarcinomas ranged from well differentiated to poorly
differentiated, stages I–IV, with a mix of intestinal- and diffuse-
type tumors.
DNA bisulfite treatment and pyrosequencing analysis
DNA from cell lines and the primary tissue samples were
purified using a DNeasy tissue kit (Qiagen, Valencia, CA, USA).
The bisulfite modification of the DNA was performed using an
EZ DNA Methylation-Gold Kit (ZYMO Research, Orange, CA,
USA), according to the manufacturer’s protocol. A 40 ng aliquot
of modified DNA was subjected to PCR amplification of the
specific promoter region containing a CpG island, by use of a
primer set designed to amplify both methylated and unmethy-
lated sequences of the MT3 gene. The primers were designed
using PSQ assay design software (Qiagen), where one of the
Table 1. Primers used for pyrosequencing, qRT-PCR, and ChIP analysis.
Forward primer Reverse primer Sequencing primer
Pyrosequencing
MT3-assay1 GGGTTAGGAGTTAAGGATTTGAAG Bio-CTCCAAAACCCCAAATCTATTCA TGAAGATGTTAGGTAGGATA (5s)
MT3-assay2 AGGTAGGGAAGAGTTGGGAAATA Bio-CCACACACCCACTACATCTATC CCACACACCCACTACATCTATC (2s);
GGGGAGTGGGTTGGTA (1s);
GATGAGGGGTGGGAG (3s)
MT3-assay3 AGGATGAGGGGTGGGAGT Bio-CAACAAATAACCATACTTTTATAAC GGTAGTGTATATATAAGGTAGG (4as);
TAAGAGTATAAAAGGAAAGA (4ds);
GAGTTTAGAGGGTTTGGTAT (4bs)
MT3-assay4 GATTTGTTTTTGTTTTTTTGGTGA Bio-ACCCTTCCCCCAAATATCCTT TTTGTTTTTTTGGTGAGT (7s)
ChIP
ChIP1 GGAAGAGAGGCAGGGAAGAG AGCGCGCACGTACCATCT
ChIP2 TCTCCACTTTCGGAGATGGT GCGTGCACGACCCACT
ChIP3 AAGCGCACAAACGGAAAG GTGGCGATGCTTTTATAGCC
qRT-PCR
MT3 GACATGGACCCTGAGACCTG TCCTTGGCACACTTCTCACA
doi:10.1371/journal.pone.0022009.t001
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sequence the whole promoter region from 2372 to +344
(Figure 1A). The primers’ sequences are given in Table 1.
Platinum PCR SuperMix High Fidelity (Invitrogen) was used to
prepare the PCR solution. The resultant PCR products were
checked by gel electrophoresis to confirm the size of the product
and rule out the formation of primer dimer. The specific PCR
products were then subjected to quantitative pyrosequencing
analysis using a Biotage PyroMark MD system (Qiagen) following
the protocol provided by the manufacturer. The results were
analyzed by Pyro Q-CpG 1.0.9 software (Qiagen). Based on
control normal samples and internal quality controls provided in
the software analysis, we used 10% as a cutoff for identification of
DNA hypermethylation [35]. Statistical analysis was performed
to detect significant changes in the frequencies of DNA
methylation of CpG nucleotides between tumor and normal
samples.
Based on the pyrosequencing data, we got the methylation level
(%) of each CpG sites (from 2372 to +344) from each individual
sample including NS, NG, BE, and BAEs. We plotted these data
into a heat map using xxx software.
Quantitative real-time RT-PCR (qRT-PCR) analyses of MT3
expression
Total RNAs from all the cell lines and primary tissue samples
were isolated using the RNeasy mini kit (Qiagen), and single-
stranded cDNA was subsequently synthesized using the iScript
cDNA synthesis kit (Bio-Rad, Hercules, CA, USA). The primers
were designed using the online software, Primer 3 (http://frodo.
wi.mit.edu/cgi-bin/primer3/primer3_www.cgi). The forward and
reverse primers were designed to span two different exons. The
primers’ sequences are given in Table 1. The oligos were obtained
from Integrated DNA Technologies (Coralville, IA, USA). The
qRT-PCR was performed using an iCycler (Bio-Rad) with the
threshold cycle number determined by use of iCycler software
version 3.0. Reactions were performed in triplicate, and the
threshold numbers were averaged. The results of these genes were
normalized to HPRT1, which had minimal variation in all normal
and tumor samples tested [45]. Expression fold was calculated
according to the formula 2
(Rt–Et)/2
(Rn–En) [45], where Rt is the
threshold cycle number for the reference gene observed in the
tumor, Et is the threshold cycle number for the experimental gene
observed in the tumor, Rn is the threshold cycle number for the
Figure 6. MT3 methylation of is associated with advanced tumor stage and lymph node metastasis. A) Increased DNA methylation of
MT3 promoter R2 (2127 to 28 sites) correlates with advanced tumor staging (P=0.005). B) DNA methylation of MT3 promoter R2 (2127 to 28 sites)
correlates with lymph node metastasis (P=0.03). C) DNA methylation of MT3 promoter R3 (+28 to +344 sites) correlates with tumor staging (P=0.03).
D) DNA methylation of MT3 promoter R3 (+28 to +344 sites) does not correlate with lymph node status (P=0.4).
doi:10.1371/journal.pone.0022009.g006
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threshold cycle number for the experimental gene observed in the
normal samples. Rn and En values were calculated as an average of
30 normal samples.
5-Aza-29-deoxycytidine (5-Aza) and Trichostatin-A (TSA)
treatment
For validation of the role of DNA methylation in transcrip-
tional regulation in vitro, an esophageal cancer cell line (OE33)
was maintained in Dulbecco’s modified Eagle’s medium
(DMEM), supplemented with 10% fetal bovine serum (FBS)
and antibiotics (Invitrogen). Cells were seeded at low density for
24 h, and then treated with 5 mM 5-Aza (Sigma-Aldrich, St
Louis, MO, USA) for 72 h and/or 200 nM TSA (Wako, Osaka,
Japan) for 24 h. Total RNA and DNA were isolated and purified
by the RNeasy kit and the DNeasy tissue kit (Qiagen) as
described above. DNA methylation levels of MT3 in the samples
before and after treatments were determined by pyrosequencing,
and mRNA expression levels were determined by qRT-PCR as
described above. For ChIP assay, chromatins from OE33 cells
(after 5-Aza administration) were harvested following the
protocol described in the section of chromatin immunoprecip-
itation (ChIP) assay.
Chromatin immunoprecipitation (ChIP) assay
To check the role of histone modifications in the MT3
promoter region, chromatin immunoprecipitation (ChIP) assay
was carried out [46]. In brief, chromatin in confluent cells of
OE33 and FLO-1 lines was cross-linked and harvested, and the
protein-chromatin lysate was fragmented to a length between 200
and 1,000 bp by sonication. The chromatin was precleaned by
incubating with protein G agarose and then immunoprecipitated,
with rotation, overnight at 4uC with the antibodies against
histone 3 (H3), anti-acetylated histone H3K9 (H3K9ace, #9671,
1:50, Cell Signaling, Danvers, MA, USA), dimethylated histone
H3K4 (H3K4me2, #9725, 1:50, C64G9, Cell Signaling),
dimethylated histone H3K9 (H3K9me2, #9753, 1:25, Cell
Signaling). The precipitated chromatin was then harvested by
protein G agarose and eluted in elution buffer after a series of
washing. A ChIP DNA clean & concentration kit (ZYMO
Research) was used on the chromatin following the manufactur-
er’s instructions. The ChIP DNA was eluted in a final 50 ml
volume, and 2 mL of each ChIP DNA was subjected to
quantitative analysis by real-time PCR (qPCR). Primers were
designed to amplify 3 regions in the MT3 promoter area as
shown in Figure 1A. The primers’ sequences are given in Table 1.
Fold enrichment in the binding of histones (H3K4me2,
H3K9ace, and H3K9me2) to MT3 promoter regions in each
immunoprecipitation was normalized to the indicated histone
binding level in its corresponding input and H3 levels in input
DNA. Two independent ChIP experiments were performed for
each analysis, and qPCR was performed twice for each of the
ChIP DNA samples. The standard deviation among the
experiments did not exceed 10% of the average values. The
average values of the three histones were graphed to demonstrate
the relative percent of occupancy.
Statistical analysis
The Mann-Whitney test was used 1) to compare the DNA
methylation level between NS and NG, and 2) to compare the
mRNA expression fold between normal and tumor samples.
ANOVA of Newman-Keuls test was used to compare the
differences of the average DNA methylation level among N, BE
and EAC. The significance in the DNA methylation level of each
individual CpG site between EAC and normal samples was
calculated using the Tukey method and expressed as false
discovery rate (FDR) [47], then plotted as 2log10(FDR). The
correlations between the DNA methylation level and mRNA
expression fold were determined by Spearman Correlation. All p-
values were based on two-sided tests and differences were
considered statistically significant when p-value#0.01.
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